Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mediwound Ltd Ord Sh (NQ: MDWD ) 18.26 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Mediwound Ltd Ord Sh < Previous 1 2 Next > MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns August 15, 2024 Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages From MediWound Ltd. Via GlobeNewswire MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update August 14, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) August 05, 2024 NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients From MediWound Ltd. Via GlobeNewswire MediWound to Report Second Quarter 2024 Financial Results August 02, 2024 Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers July 29, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program July 16, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces $25 Million Strategic Private Placement Financing July 15, 2024 Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment From MediWound Ltd. Via GlobeNewswire MediWound Reports First Quarter 2024 Financial Results and Provides Company Update May 29, 2024 From MediWound Ltd. Via GlobeNewswire MediWound to Report First Quarter 2024 Financial Results May 22, 2024 Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences April 25, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session April 17, 2024 Via Investor Brand Network MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update March 21, 2024 From MediWound Ltd. Via GlobeNewswire MediWound to Report Fourth Quarter and Full Year 2023 Financial Results March 14, 2024 Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study February 12, 2024 Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... From MediWound Ltd. Via GlobeNewswire MediWound to Participate in Two Upcoming Investor Conferences February 05, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns January 09, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army December 28, 2023 Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million From MediWound Ltd. Via GlobeNewswire MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads December 21, 2023 Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement From MediWound Ltd. Via GlobeNewswire MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update November 21, 2023 From MediWound Ltd. Via GlobeNewswire MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer November 21, 2023 From MediWound Ltd. Via GlobeNewswire MediWound to Report Third Quarter 2023 Financial Results November 14, 2023 Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients November 13, 2023 The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages From MediWound Ltd. Via GlobeNewswire MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe November 08, 2023 NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients From MediWound Ltd. Via GlobeNewswire MediWound Announces Collaboration with 3M on EscharEx® Phase III Study October 11, 2023 MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers From MediWound Ltd. Via GlobeNewswire MediWound Deploys NexoBrid® for Emergency Supply October 09, 2023 From MediWound Ltd. Via GlobeNewswire MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults September 21, 2023 Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns From MediWound Ltd. Via GlobeNewswire MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress September 11, 2023 From MediWound Ltd. Via GlobeNewswire MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From MediWound Ltd. Via GlobeNewswire MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update August 15, 2023 From MediWound Ltd. Via GlobeNewswire MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study August 15, 2023 MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers From MediWound Ltd. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.